Neuronetics® Hits Major Milestones with More Than 2.5 Million Treatments and 1,000 Installations of Its NeuroStar® Advanced Therapy System

Neuronetics® Hits Major Milestones with More Than 2.5 Million Treatments and 1,000 Installations of Its NeuroStar® Advanced Therapy System

Publication date: Mar 17, 2020

An increasing number of patients and providers are turning to the transcranial magnetic stimulation (TMS) market leader as a proven, non-drug treatment option for depression MALVERN, Pa. , March 16, 2020 (GLOBE NEWSWIRE) — Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced it has delivered over 2. 5 million treatments with its NeuroStar(R) Advanced Therapy transcranial magnetic stimulation (TMS) system, in addition to recently exceeding 1,000 device installations in the United States.

These important milestones further demonstrate NeuroStar as a much-needed, non-drug treatment option for adults with Major Depressive Disorder (MDD) that is helping to tackle the country’s critical depression issue.

Unlike electroconvulsive therapy (ECT), NeuroStar TMS is a non-drug, non-invasive treatment that uses magnetic pulses to stimulate areas of the brain that are underactive in depression. 4,5 Since receiving FDA clearance in 2008 as a safe and effective treatment for adult patients with MDD, NeuroStar has become a trailblazer in the treatment of depression and is the number one TMS choice of doctors.

-These milestones indicate that doctors continue to trust NeuroStar as the number one TMS choice in the country and, as a result, more men and women with depression are getting access to this non-drug treatment that has the potential to be life-changing,” said Dan Guthrie, Chief Commercial Officer of Neuronetics, Inc. -We are so proud of how far we’ve come over the last decade, but we know there’s still work to do.

In an open-label clinical trial, 58 percent of patients significantly responded to treatment and 37 percent achieved complete remission of their depression symptoms with NeuroStar. 6 Treatment sessions can be performed in as little as 19 minutes**- patients have the flexibility to fit it within their busy lives, and doctors can see more patients, allowing them to provide NeuroStar TMS to a growing patient population.

About NeuroStar(R) Advanced Therapy NeuroStar(R) Advanced Therapy is the market leader in transcranial magnetic stimulation (TMS), a non-invasive form of neuromodulation, and the #1 TMS choice of doctors for patients with Major Depressive Disorder (MDD).

In an NIMH-funded, independent, randomized controlled trial, patients treated with TMS using a clinical-trial version of the NeuroStar TMS System were 4. 2 times more likely to achieve remission compared to patients receiving sham treatment (P = 0. 02; odds ratio = 4. 05). 7 The most common side effect is pain or discomfort at or near the treatment site, which usually resolves within one week.

Concepts Keywords
Antidepressant UnderJapan snational insurance
Antidepressants Psychiatric disorders
Bea Men women depression
Brain Electroconvulsive therapy
Catalyst Medicine
Cleveland Clinic Psychiatry
Clinical Trial Branches of biology
Contraindicated Neurotechnology
Depression Treatment of depression
Electroconvulsive Therapy Neurophysiology
FDA Neuropsychology
Healthcare Transcranial magnetic stimulation
Insurance Neuromodulation
Licensed Professional Counselor Major depressive disorder
Major Depressive Disorder Electroconvulsive therapy
Odds Ratio
Patient Advocate
Psychiatric Disorders
Randomized Controlled Trial
Registered Trademark
Transcranial Magnetic Stimulation
United States


Type Source Name
drug DRUGBANK Coenzyme M
disease MESH men
disease MESH depression
disease MESH Major Depressive Disorder
drug DRUGBANK Nonoxynol-9
disease MESH psychiatric disorders
drug DRUGBANK Tilmicosin
pathway REACTOME Release

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *